![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 Amino Acids that Are Implicated in the Coupling of Binding to Channel GatingDepartment of Pharmacology, University College London, Gower Street, London, United Kingdom (G.T.Y., N.S.M.); and Eli Lilly & Co. Ltd., Lilly Research Centre, Windlesham, Surrey, United Kingdom (L.M.B., R.Z., P.C.A., M.B., E.S.)
Received for publication September 12, 2006.
Accepted for publication October 25, 2006.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
4-containing receptors. TMAQ also exhibits remarkable species selectivity, being a potent agonist of nAChRs containing the human 4 subunit but having no detectable agonist activity on nAChRs containing the rat 4 subunit. With the aim of identifying subunit domains and individual amino acids, which contribute to the species selectivity of TMAQ, a series of chimeric and mutated 4 subunits has been constructed. Recombinant receptors containing wild-type, chimeric, or mutated 4 subunits have been examined by radioligand binding, intracellular calcium assays, and electrophysiological recording. Two adjacent amino acids located within the extracellular loop D domain of the 4 subunit (amino acids 55 and 56) have been identified as playing a critical role in determining the agonist potency of TMAQ. Mutagenesis of these two residues within the rat 4 subunit to the corresponding amino acids in the human 4 subunit (S55N and I56V mutations) confers sensitivity to TMAQ. The converse mutations in the human 4 subunit (N55S and V56I) largely abolish sensitivity to TMAQ. In contrast, these mutations have little or no effect on sensitivity to the nonselective nicotinic agonist epibatidine. Despite acting as a potent agonist of human 4-containing nAChRs, TMAQ acts as an antagonist of rat 4-containing receptors. Our experimental data, together with homology models of the rat and human 
34 nAChRs, suggest that amino acids 55 and 56 may be involved in the coupling of agonist binding and channel gating.
; Millar, 2003, 2006). In addition to nAChRs expressed at the neuromuscular junction (which are assembled from five different subunits: 1, 1, 
, 
, and 
), a heterogeneous population of neuronal nAChRs is expressed within the central and peripheral nervous systems. Twelve neuronal nAChR subunits (2-10 and 2-4) have been identified in vertebrates, all of which (with the exception of 8) are expressed in mammals. The influence of subunit composition upon the pharmacological diversity of nAChRs is incompletely understood but is being investigated by a variety of experimental approaches. There is strong evidence, for example, that receptors containing 4 and 2 subunits are important subtypes within the brain, whereas receptors containing 3 and 4 subunits are important postsynaptic receptors in autonomic ganglia (McGehee and Role, 1995).
Neuronal nAChRs have been implicated in several neurological disorders and are being seen increasingly as important target sites for therapeutic drug discovery (Lloyd and Williams, 2000; Jensen et al., 2005). As a consequence, considerable efforts have been aimed at identifying subtypeselective nAChR ligands. As part of a program aimed at the development of subtype-selective nAChR agonists, a series of compounds has been identified that exhibits selectivity for nAChRs containing the 4 subunit. Here we describe one such compound, 5-(trifluoromethyl)-6-(1-methyl-azepan-4-yl)-methyl-1H-quinolin-2-one (TMAQ) (Fig. 1), a novel nicotinic agonist that exhibits selectivity for 4-containing nAChRs. It is interesting that TMAQ also exhibits strong species selectivity. TMAQ is a potent agonist of receptors containing the human 4 subunit but not of receptors containing the rat 4 subunit. This is somewhat surprising, given the relative similarity in the primary amino acid sequence of the human and rat 4 subunits.
|
In the present study, we identified amino acids responsible for conferring species selectivity of TMAQ by the construction and characterization of a series of chimeric and mutated 4 subunits. Recombinant nAChRs have been examined by radioligand binding, intracellular calcium assays, and by electrophysiological recording. Experimental data are interpreted with reference to homology models of the human and rat 34 nAChR extracellular domain, which are based on the atomic resolution structure of the acetylcholine binding protein (AChBP) from Lymnaea stagnalis (Brejc et al., 2001; Celie et al., 2004).
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
1.32-1.92 (7H, m), 2.34 (3H, s), 2.43-2.68 (4H, m), 2.83 (2H, d), 6.81-8.23 (4H, m), 12.92 (1H, br s); flow injection analysis-mass spectrometry MH+= 339.
Subunit cDNAs, Subunit Chimeras, and Site-Directed Mutagenesis. Human nAChR 3 and 4 subunit cDNAs (Elliott et al., 1996) were obtained from Merck Research Laboratories (La Jolla, CA). Rat nAChR 3 and 4 subunit cDNAs (Boulter et al., 1986; Duvoisin et al., 1989) were provided by Jim Patrick (Baylor College of Medicine, Houston, TX). All nAChR subunit cDNAs were subcloned into plasmid expression vector pcDNA3 (Invitrogen, Paisley, UK). A unique BstEII restriction site, present in both the rat and human 4 subunit cDNAs, located between the second and third transmembrane domains, was used to construct chimeric cDNAs in which the N- and C-terminal regions were exchanged (h/r4 and r/h4). Site-directed mutagenesis of nAChR subunit cDNAs was performed using the QuikChange mutagenesis kit (Stratagene, Amsterdam, the Netherlands). All chimeric and mutated subunits were verified by nucleotide sequencing using the Big Dye Terminator Cycle Sequencing kit and ABI Prism 3100-Avant automated sequencer according to the manufacturer's instructions (Applied Biosystems, Warrington, UK).
Mammalian Cell Lines Stably Expressing nAChRs. Human embryonic kidney (HEK) 293 cell lines stably expressing human recombinant neuronal nAChR subtypes 24, 34, 44, and 42, andaGH4C1 cell line stably expressing the human 7 nAChR were obtained from Merck Research Laboratories. Conditions used to culture these stable cell lines have been described previously (Broad et al., 2002). A human embryonic rhabdomyosarcoma cell line (RD) expressing the muscle-type nAChR was obtained from the American Type Culture Collection (Manassas, VA).
Transient Expression of nAChRs in Mammalian Cells. Human kidney tsA201 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal calf serum (Sigma, Poole, UK), penicillin (100 U/ml), and streptomycin (100 mg/ml) (Invitrogen). Cells were maintained in a humidified incubator containing 5% CO2 at 37°C. Cells were transfected using the Effectene reagent (QIAGEN, Crawley, UK) according to the manufacturer's instructions. After overnight incubation in Effectene, cells were incubated at 37°C for 24 h before being assayed for radioligand binding or intracellular calcium recording.
Radioligand Binding. [3H]Epibatidine (55.5 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Beaconsfield, UK). Radioligand binding to transiently transfected tsA201 cells was performed essentially as described previously (Baker et al., 2004). Cell membranes (typically 80-150 µg of protein) were incubated with radioligand for 150 min at 4°C in a total volume of 300 µl in the presence of protease inhibitors leupeptin (2 µg/ml) and pepstatin (1 µg/ml). Nonspecific binding was determined in the presence of nicotine (1 mM) and carbamylcholine (1 mM). To avoid ligand depletion, binding was performed in a larger volume (2 ml) for concentrations of [3H]epibatidine lower than 0.3 nM. Radioligand binding was assayed by filtration onto Whatman GF/B filters (presoaked in 0.5% polyethylenimine), followed by rapid washing with ice-cold 10 mM phosphate buffer using a Brandel cell harvester. Bound radioligand was quantified by scintillation counting. For competition binding experiments with TMAQ, a fixed concentration (typically 0.3 nM) of [3H]epibatidine was used. IC50 values were converted to Ki values using the equation Ki = IC50/1 + ([L]/Kd), in which L is the free concentration of [3H]epibatidine used in the assay and Kd is the dissociation constant for binding of [3H]epibatidine. Curves for equilibrium binding were fitted with the Hill equation using Prism version 4 (GraphPad Software, San Diego, CA).
Intracellular Calcium Assays. Transfected tsA201 cells were replated onto poly(L-lysine)-coated black-walled 96-well plates (Marathon Laboratories, London, UK) approximately 18 to 20 h after transfection. After 
24 h, cell medium was removed, and the cells were incubated in 50 to 100 µl of 1 µM Fluo-4 acetoxymethyl ester (Invitrogen) in Hanks' balanced salt solution with 0.02% Pluronic F-127 (Invitrogen) for 45 to 60 min at room temperature. Cells were rinsed once with 160 µl of assay buffer (Hanks' balanced salt solution supplemented with 18.8 mM CaCl2, 8.8 mM sucrose, and 6.3 mM HEPES), and the cells were assayed using a fluorometric imaging plate reader (FLIPR) (Molecular Devices, Winnersh, UK), as described previously (Lansdell et al., 2005). Drug dilutions in assay buffer were prepared in a separate 96-well plate. Parameters for drug addition to the cell plate were preprogrammed, and delivery was automated through a 96-tip head pipettor. Experimental conditions for FLIPR experiments conducted with stably transfected HEK 293 and GH4C1 cells and with cultured human rhabdomyosarcoma RD cells were as described previously (Broad et al., 2002; Craig et al., 2004). Dose-response curves were constructed by measuring peak responses with TMAQ and normalizing to maximal peak response with acetylcholine or epibatidine. Curve-fitting was performed with GraphPad Prism version 4 (GraphPad Software).
|
3, human 4, and rat 4 subunit coding sequences were suspended in distilled water and injected into the nuclei of the oocytes immediately after the collagenase treatment using a Drummond variable volume microinjector. Subunit cDNAs were coinjected in a 1:1 ratio, and approximately 2 ng of cDNA was injected in a total injection volume of 18.4 nl/oocyte. After injection, oocytes were incubated at 18°C in a modified Barth's solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.3 mM Ca(NO3)2, 0.41 CaCl2, 0.82 mM MgSO4, 15 mM HEPES, and 50 mg/l neomycin, pH 7.6 with NaOH (osmolarity, 235 mOsM). Experiments were performed on oocytes after 3 to 5 days of incubation. Oocytes were placed in a recording chamber (internal diameter, 3 mm), which was continuously perfused with a saline solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 10 mM HEPES, pH 7.3 with NaOH, 235 mOsm) at a rate of 10 ml/min. Dilutions of drugs in external saline were prepared immediately before the experiments and applied by switching between control and drug-containing saline using a BPS-8 solution exchange system (ALA Scientific Inc., Westbury, NY). Agonist applications were alternated by 5 min of superfusion with agonist-free saline to allow the receptors to recover from desensitization. Oocytes were impaled by two microelectrodes filled with 3 M KCl (0.5-2.5 M
) and voltage-clamped using a Geneclamp 500B amplifier (Molecular Devices). The external saline was clamped at ground potential by means of a virtual ground circuit using an Ag/AgCl reference electrode and a Pt/Ir current-passing electrode. The membrane potential was held at -60 mV. The current required to keep the oocyte membrane at the holding potential was measured. Membrane currents were low-pass-filtered (four-pole low-pass Bessel filter, -3dB at 100 Hz), digitized (300 Hz), and stored on disk for offline computer analysis. Data are expressed as mean ± S.E.M. All experiments were performed at room temperature. For antagonist concentration-response experiments an EC20 concentration of ACh (30 µM) was applied for 45 s. After 15 s of ACh application, ACh was coapplied with antagonist for 15 s, after which another 15-s period followed of ACh application in the absence of antagonist. Current amplitudes at the end of the coapplication of ACh with antagonist were measured and normalized to the current amplitudes of the ACh control response just before coapplication. Concentration-response curves were fitted to the data obtained in separate experiments, and mean ± S.E.M. of estimated parameters were calculated for n oocytes. Standard inhibition curves were fitted according to the equation i/imax = 1/{1 + ([antagonist]/IC50)nH. Curve-fitting was performed using Prism version 4 (GraphPad Software).
Computer Modeling. A homology model of the human 34 nAChR extracellular domain was constructed using the crystal structure of the Lymnaea stagnalis AChBP with bound nicotine (Protein Data Bank code 1UW6; protomer units A&E) as a starting template (Celie et al., 2004). Amino acid sequence alignments were generated using the CLUSTAL X program (Thompson et al., 1997). Nicotinic receptor 3 and 4 subunit models were generated with the MODELER program (Sali and Blundell, 1993), and individual 3 and 4 subunit models were then refitted back onto the AChBP structure to generate an 34 subunit dimer model in which 3 corresponds to the principal subunit and 4 to the complementary subunit.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
4-containing nAChRs (24, 34, and 44). In contrast, little or no agonist activity was observed on human recombinant 42 or 7 nAChRs or on native human muscle-type nAChRs expressed in the rhabdomyosarcoma RD cell line (Fig. 2).
The ability of TMAQ to act as an agonist of human 34 nAChRs was confirmed by FLIPR-based assays with transiently transfected human embryonic kidney cells (Fig. 3A). Despite clear evidence that TMAQ acts as a potent agonist of human 34 nAChRs (EC50 = 0.2 ± 0.1 µM; n = 4), TMAQ displayed no detectable agonist activity in cells transfected with rat 34 nAChRs (Fig. 3B). In contrast, epibatidine acted as a potent agonist of both human and rat 34 nAChRs (Fig. 3, A and B). To examine the contribution of 3 and 4 subunits to TMAQ sensitivity, experiments were performed with human-rat hybrid nAChRs. Responses to TMAQ were detected in cells expressing the rat 3 subunit with human 4 (EC50 = 0.3 ± 0.03 µM; n = 3), but not in cells transfected with human 3 subunit with rat 4 (Fig. 3C). This provided evidence that the species-selectivity of TMAQ was a consequence of differences in the human and rat 4 subunits.
|
4 and r/h4) were constructed using a unique BstEII site located within the M3 transmembrane domain of both subunits. Alignments of the human and rat 4 subunit amino acid sequences revealed that their mature proteins differ by 82 amino acids. Of these amino acid differences, 19 are located in the region N-terminal to the BstEII site that was used to construct the chimeras (Fig. 4), and 63 are C-terminal to this site. The ability of TMAQ to activate nAChRs containing the human/rat and rat/human 4 subunit chimeras (h/r4 and r/h4) was examined by FLIPR-based intracellular calcium assays. Cells were cotransfected with the human 3 subunit in combination with wild-type or chimeric 4 subunits. In all cases, responses to TMAQ were compared with maximal responses obtained with epibatidine, an agonist that activates both human 4 (h4) and rat 4 (r4) containing nAChRs. As shown in Fig. 5, TMAQ induced dose-dependent responses in cells transfected with either the h4 subunit or the h/r4 subunit chimera. The EC50 value (0.1 ± 0.1 µM; n = 4) and maximum response observed with nAChRs containing the h/r4 subunit chimera were not significantly different from that observed with h3 + h4 nAChRs. In contrast, no responses were detected to TMAQ, even at high agonist concentrations, in cells transfected with either the r4 subunit or with the r/h4 subunit chimera (Fig. 5).
|
|
The previous findings indicate that species-selectivity of TMAQ is conferred by residues present within the N-terminal region of the 4 subunit. Of the 19 amino acid differences in the N-terminal region of the 4 subunits, two amino acids (at positions 55 and 56), which are located within the loop D domain of the 4 subunit, were examined by site-directed mutagenesis. As shown in Fig. 4, the human 4 subunit contains asparagine and valine at these positions, whereas the rat 4 subunit contains serine and isoleucine. Initially both amino acids were mutated individually in the rat 4 subunit to their corresponding amino acids in the human 4 subunit (to create mutated subunits r4S55N and r4I56V).
|
|
4 subunits (coexpressed with human 3) were examined by means of FLIPR-based intracellular calcium assays. As illustrated in Fig. 6A, when the human 3 subunit was coexpressed with either of the singly mutated rat 4 subunits (r4S55N or r4I56V), nAChRs were generated that were sensitive to TMAQ. In both cases, however, a lower maximal response was seen for nAChRs containing the mutated r4 subunits than for nAChRs containing the wild-type human 4 subunit (Fig. 6A). The maximum responses observed with r4S55N and r4I56V were 58 ± 9% (n = 4) and 26 ± 3% (n = 3) of the maximum response detected with the wild-type human 4 subunit. Further mutagenesis was performed to create a rat 4 subunit containing both of these mutations (r4S55N,I56V). The EC50 value and maximum response observed with TMAQ upon receptors containing the human 3 subunit coexpressed with r4S55N,I56V was indistinguishable from that observed with the wild-type human 34 nAChRs (Fig. 6A). In contrast, mutation of two adjacent amino acids within the loop E domain of the rat 4 subunit (to create r4I118V,Q119L) had no effect on maximal agonist responses with TMAQ when examined by FLIPR-based intracellular calcium assays (data not shown).
To confirm the influence of the two loop D amino acids upon the species-selectivity of TMAQ, a series of mutations was created within the human 4 subunit. The two amino acids within the human 4 subunit were mutated individually and in combination to create mutated subunits h4N55S, h4V56I, and h4N55S,V56I. As previously, the mutated subunits were coexpressed with the human 3 subunit and examined by a FLIPR-based intracellular calcium assay (Fig. 6B). Receptors containing the h4V56I mutation did not exhibit a significant reduction in maximal agonist response observed with TMAQ, but receptors containing the h4N55S mutation showed a maximum response to TMAQ, which was 69 ± 2% (n = 4) of that with the human 4 subunit. An even more dramatic reduction in maximal response with TMAQ was observed in receptors containing h4N55S,V56I (maximum responses with TMAQ were reduced to 51 ± 5%; n = 3 of that observed with the human 4 subunit). Thus, although sensitivity to TMAQ was not completely abolished by mutation of the human 4 subunit (Fig. 6B), these findings, taken together with the dramatic results observed with the mutated rat 4 subunit (Fig. 6A), help to demonstrate the importance of these two adjacent amino acid in conferring species-selectivity of TMAQ.
Competition radioligand binding was performed to examine the affinity of TMAQ binding to nAChRs containing wildtype and mutated 4 subunits. Saturation binding studies were first performed to determine the affinity of [3H]epibatidine for nAChRs containing the human 3 subunit coexpressed with either human 4orrat 4 (Fig. 7A). Epibatidine bound with a similar high affinity to both nAChRs. The calculated Kd values were not significantly different for h3 + h4 nAChRs (0.34 ± 0.02 nM; n = 3) and h3 + r4 nAChRs (0.33 ± 0.03 nM; n = 3). Competition binding studies were then performed to determine the affinity of TMAQ binding to nAChRs containing the human 3 subunit coexpressed with wild-type and mutant 4 subunits (Fig. 7B). TMAQ bound with high affinity to h3 + h4 nAChRs (Ki = 1.2 ± 0.1 nM; n = 3) but with significantly lower affinity (P = 0.028) to h3 + r4 nAChRs (Ki = 17 ± 5 nM; n = 3). TMAQ binding to nAChRs containing r4S55N,I56V (Ki = 2.2 ± 0.6 nM; n = 3) was not significantly different to the high-affinity binding seen to nAChRs containing the human 4 subunit. TMAQ binding to nAChRs containing h4N55S,V56I (Ki = 11 ± 3 nM; n = 3) was not significantly different from the lower-affinity binding to nAChRs containing the rat 4 subunit. We can conclude that amino acids 55 and 56 are responsible for a modest but significant (5- to 14-fold) difference in the affinity of binding of TMAQ to nAChRs containing the human and rat 4 subunit. Thus, although TMAQ exhibits little or no agonist activity of r4-containing nAChRs, it retains the ability to bind to r4-containing nAChRs with high affinity. In contrast, competition binding experiments revealed that TMAQ bound to recombinant human 42 and 7 nAChRs with much lower affinity (1.3 ± 0.1 and >30 µM, respectively; n = 3; data not shown).
|
34 nAChRs expressed in X. laevis oocytes (Fig. 8). Acetylcholine induced large inward currents in oocytes expressing h3 + h4, h3 + r4, and h3 + r4S55N,I56V nAChRs, whereas agonist responses to TMAQ were detected only in oocytes expressing h3 + h4 and h3 + r4S55N,I56V (Fig. 8A), findings that are in agreement with the data obtained by intracellular calcium recordings. Dose-response experiments were performed (Fig. 8B), which revealed that TMAQ had no significant agonist activity on h3 + r4 nAChRs (at concentrations up to 10 µM) but was a potent agonist of h3 + h4 nAChRs (EC50 = 0.5 ± 0.1 µM; n = 3). TMAQ was also a potent agonist on h3 + h4N55S,V56I nAChRs, with an EC50 of 0.3 ± 0.1 µM (n = 3), which is not significantly different from that observed on h3 + h4 nAChRs (Fig. 8B).
It is interesting that when TMAQ was coapplied with ACh to oocytes expressing h3 + r4, evidence of dose-dependent, reversible antagonism was observed (Fig. 9, A and B). The antagonist activity of TMAQ on h3 + r4 nAChRs was examined further by construction of ACh dose-response curves in the absence and presence of TMAQ (Fig. 9C). TMAQ caused a significant rightward shift of the ACh doseresponse curve (P = 0.014, for both 1 and 10 µM TMAQ). The EC50 for ACh determined in the absence of TMAQ was 107 ± 8 µM (n = 3) but was 177 ± 15 µM (n = 3) in the presence of 1 µM TMAQ and 407 ± 71 µM (n = 3) in the presence of 10 µM TMAQ. TMAQ caused a reduction in the maximal ACh response (91 ± 4% of maximum with 1 µM TMAQ and 84 ± 3% of maximum with 10 µM TMAQ). The voltage-dependence of TMAQ's antagonist activity was examined by determining the % inhibition caused by 1 µM TMAQ upon responses to 100 µM ACh at a range of holding potentials (from -20 to -100 mV; Fig. 9D). Taken together, these results suggest that the antagonist activity of TMAQ on h3 + r4 nAChRs is at least partly a consequence of noncompetitive antagonism caused by channel block.
|
34 nAChR was generated (Fig. 10) based on the atomic-resolution structure of the L. stagnalis AChBP with bound nicotine (Celie et al., 2004). Examination of this homology model, together with a model described previously of the rat 34 nAChRs (Costa et al., 2003), indicates that amino acids 55 and 56 of the 4 subunit do not lie within the interaction shell of the agonist binding site (Fig. 10).
|
34 homology models, amino acid 55 (Ser55 in r4 and Asn55 in h4) is predicted to be external to the nAChR subunit core (Fig. 10) and is located at the interface of the 4 and 3 subunits. The main subunit interactions in this region are between loop domains linking -sheet structures (the 4-5 loop on the 3 subunit and the 1-2 loop on the 4 subunit). In the human 34 model, the Asn55 amine side chain is 4 Å from the backbone amide carbonyl, whereas in the rat 34 model, the Ser55 hydroxyl side chain is 5.3 Å from this position. This suggests that a hydrogen bond interaction would be possible for Asn55 but, if present, would be much weaker for Ser55. Hence, the mutation r4S55N may help to stabilize subunit-subunit interactions and may account for the increased maximal response of TMAQ (Fig. 6). It should be noted, however, that there is a single amino acid insertion in the nAChR 3 sequence (YNNAV) compared with the AChBP sequence (YN-AI) within the 4-5 loop region of the principal subunit. As a consequence, accurate modeling of this region is difficult.
Based on the nAChR 34 homology models, amino acid 56 (Ile56 in r4 and Val56 in h4) is predicted to be internal to the nAChR subunit core (Fig. 10). The surrounding residues are hydrophobic in nature and would be predicted to stabilize the subunit tertiary structure. The increase in the maximal response for TMAQ observed with the r4I56V mutant (Fig. 6A), and the decrease in maximal response for the h4V56I mutant (Fig. 6B) highlights how the replacement of one branched hydrophobic side chain for another similar side chain results in only a relatively small effect on TMAQ efficacy. It is, perhaps, logical that an increase in side-chain size (in h4V56I) might result in a reduction in agonist efficacy (Fig. 6B) as a result of perturbation of the hydrophobic subunit core, but it is interesting that a decrease in side-chain size (in r4I56V) causes an increase in agonist efficacy for TMAQ (Fig. 6A).
It is possible that the effect of the mutations within the 34 nAChR is to create a binding site in the locality of the mutations that is suitable for TMAQ to stabilize an open conformation of the receptor. Analysis of the homology model of the rat 34 nAChR (Costa et al., 2003) has identified possible alternative regions for ligand binding, which are consistent with photoaffinity-labeling experiments. However, without similar direct biophysical evidence, a binding site for TMAQ near amino acids 55 and 56 would be purely speculative. It seems more probable that TMAQ binds in a similar manner to the binding of nicotine to the AChBP (Celie et al., 2004), a conclusion that is consistent with our evidence for competitive binding of TMAQ and [3H]epibatidine (Fig. 7B).
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). In a heteromeric nAChR such as 34, the "principal" component is considered to be that contributed by the 3 subunit and the "complementary" component by 4. It has been proposed that amino acids from six discrete subunit domains (loops A-F) contribute to the nicotinic ligand binding site (Corringer et al., 2000). Three of these (loops A-C) are contributed by the principal subunit and three (loops D-F) by the complementary subunit.
At first, nAChR subunits were considered to be "agonist-binding" subunits, whereas non- subunits have been referred to as either "non-agonist-binding" or "structural" subunits (Deneris et al., 1988; Schoepfer et al., 1988). There is extensive experimental evidence, however, to indicate that non- subunits such as 4 are able to contribute to the pharmacological diversity of nAChRs (Luetje and Patrick, 1991; Parker et al., 1998). Studies using chimeric subunits and site-directed mutagenesis have demonstrated the importance of amino acids located within loops D, E, and F in determining selectivity for nicotinic agonists and antagonists (Figl et al., 1992; Czajkowski et al., 1993; Prince and Sine, 1996; Bren and Sine, 1997). Previous studies with chimeric and mutant 2 and 4 subunits have demonstrated that the loop D region between residues 54 and 63 is a major determinant of sensitivity to agonists and competitive antagonists (Harvey and Luetje, 1996; Parker et al., 2001). Within this region, residue 59 (tyrosine in 2 and lysine in 4) has been identified as being the critical residue in determining sensitivity to both agonists and antagonists.
The results presented in the present study provide further evidence that residues within loop D have a profound effect upon agonist sensitivity. In particular, we have identified two adjacent amino acids (at positions 55 and 56) as being major determinants of nAChR sensitivity to the agonist TMAQ. Note that we have numbered amino acid residues within the 4 subunit with reference to the predicted signal sequence cleavage site reported previously (Couturier et al., 1990; Gerzanich et al., 1997). Evidence for the involvement of amino acids 55 and 56 in conferring species-selective agonist activity of TMAQ has been obtained both by agonist-induced changes in intracellular calcium and by two-electrode voltage-clamp techniques. The differences in these two adjacent amino acids, located within loop D of the 4 subunit, seem to be sufficient to explain the marked difference in sensitivity of human and rat nAChRs to this agonist.
In nAChRs containing the rat 4 subunit, TMAQ retains the ability to bind (as illustrated by competition binding experiments with [3H]epibatidine; see Fig. 7B) but shows little or no agonist activity. Indeed, when TMAQ is coapplied with ACh, TMAQ displays antagonist activity on r4-containing nAChRs (Fig. 8). In this respect, TMAQ seems to be behaving similarly to the way nicotine does on chick and rat 32 nAChRs (Hussy et al., 1994). Nicotine has been shown to act as an agonist of rat 32 nAChRs but as a potent competitive antagonist of chick 32 nAChRs (Hussy et al., 1994). As we observed for TMAQ acting on human and rat 34 nAChRs, it seems that the species-selective behavior of nicotine on chick and rat 32 nAChRs can be attributed in large part to a single amino acid difference. In contrast, however, the amino acids critical for conferring species-selectivity and agonist/antagonist activity of nicotine are located within the 3 subunit and are located close to the first transmembrane domain (Hussy et al., 1994). Other studies have identified single amino acid mutations within the nAChR M2 transmembrane domain (e.g., L247T in the 7 subunit), for which antagonists of the wild-type receptor act as agonist (Bertrand et al., 1992).
The atomic-resolution structure of the AChBP from the snail L. stagnalis (Brejc et al., 2001; Celie et al., 2004) has provided a powerful tool with which to predict the structure of nAChRs. The close sequence similarity between the extracellular domain of nAChR subunits and the AChBP has enabled homology modeling and has been useful in interpreting site-directed mutagenesis studies performed with nAChRs subunits. Comparison of the AChBP and nAChR subunits indicates that the 4 amino acids 55 and 56 are located at positions analogous to Val51 and Phe52 in the AChBP (Brejc et al., 2001). Although residues within loop D of nAChRs are predicted to contribute to the agonist binding site (Corringer et al., 2000), Val51 and Phe52 do not lie in immediate proximity to the AChBP ligand binding site (Celie et al., 2004). Analysis of the homology models of the rat and human 34 nAChRs (the present study, and Costa et al., 2003), suggest that the 4 amino acids 55 and 56 are not located within the interaction shell of the agonist binding site and, therefore, may not be involved directly in agonist binding. Our data indicate that mutation of amino acids 55 and 56 has a much more profound effect upon TMAQ agonist efficacy (e.g., Figs. 6 and 8) than upon TMAQ binding (Fig. 7B). It is plausible that mutation of these amino acids may induce a conformational change that influences the affinity of TMAQ binding but a more profound and direct influence upon the coupling of agonist binding to channel opening. It is interesting that amino acids 55 and 56 lie within one of the -strand regions (2) of the AChBP (Brejc et al., 2001) adjacent to the 1-2 loop domain, which has been implicated previously in the coupling of binding and gating (Bouzat et al., 2004). Our results, together with previous studies of mutated nAChRs (Campos-Caro et al., 1996; Bouzat et al., 2004; Criado et al., 2005; Lee and Sine, 2005; Mukhtasimova et al., 2005; Sala et al., 2005; Castillo et al., 2006), indicate that amino acids located at diverse locations within the extracellular domain are able to influence the coupling of agonist binding and channel gating.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
ABBREVIATIONS: nAChR, nicotinic acetylcholine receptor; AChBP, acetylcholine binding protein; FLIPR, fluorometric imaging plate reader; TMAQ, 5-(trifluoromethyl)-6-(1-methyl-azepan-4-yl)methyl-1H-quinolin-2-one; HEK, human embryonic kidney; ACh, acetylcholine.
Address correspondence to: Dr. Neil S. Millar, Department of Pharmacology, University College London, Gower Street, London, WC1E 6BT, UK. E-mail: n.millar{at}ucl.ac.uk
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
910 nicotinic acetylcholine receptors revealed by heterologous expression of subunit chimeras. Mol Pharmacol 65: 453-460.Bertrand D, Devillers-Thiery A, Revah F, Galzi JL, Hussy N, Mulle C, Bertrand S, Ballivet M, and Changeux JP (1992) Unconventional pharmacology of a neuronal nicotinic receptor mutated in the channel domain. Proc Natl Acad Sci USA 89: 1261-1265.
Boulter J, Evans K, Goldman D, Martin G, Treco D, Heinemann S, and Patrick J (1986) Isolation of a cDNA clone coding for a possible neural nicotinic acetylcholine receptor -subunit. Nature (Lond) 319: 368-374.[CrossRef][Medline]
Bouzat C, Gumilar F, Spitzmaul G, Wang H-L, Rayes D, Hansen SB, Taylor P, and Sine SM (2004) Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel. Nature (Lond) 430: 896-900.[CrossRef][Medline]
Brejc K, van Dijk WJ, Klaassen RV, Schuurmans M, van der Oost J, Smit AB, and Sixma TK (2001) Crystal structure of an ACh-binding protein reveals the ligandbinding domain of nicotinic receptors. Nature (Lond) 411: 269-276.[CrossRef][Medline]
Bren N and Sine S (1997) Identification of residues in the adult nicotinic acetylcholine receptor that confer selectivity for curariform antagonists. J Biol Chem 272: 30793-30798.
Broad LM, Felthouse C, Zwart R, McPhie GI, Pearson KH, Craig PJ, Wallace L, Broadmore RJ, Boot JR, Keenan M, et al. (2002) PSAB-OFP, a selective 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur J Pharmacol 452: 137-144.[CrossRef][Medline]
Campos-Caro A, Sala S, Ballesta JJ, Vincente-Agulló F, Criado M, and Sala F (1996) A single residue in the M2-M3 loop is a major determinant of coupling between binding and gating in neuronal nicotinic receptors. Proc Natl Acad Sci USA 6118-6123.
Castillo M, Mulet J, Bernal JA, Criado M, Sala F, and Sala S (2006) Improved gating of a chimeric 7-5HT3A receptor upon mutations at the M2-M3 extracellular loop. FEBS Lett 580: 256-260.[CrossRef][Medline]
Celie PHN, van Rossum-Fikkert SE, van Dijk WJ, Brejc K, Smit AB, and Sixma TK (2004) Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 41: 907-914.[CrossRef][Medline]
Corringer P-J, Le Novère N, and Changeux J-P (2000) Nicotinic receptors at the amino acid level. Ann Rev Pharmacol Toxicol 40: 431-458.[CrossRef][Medline]
Costa V, Nistri A, Cavalli A, and Carloni P (2003) A structural model of agonist binding to the 34 neuronal nicotinic receptor. Br J Pharmacol 140: 921-931.[CrossRef][Medline]
Couturier S, Erkman L, Valera S, Rungger D, Bertrand S, Boulter J, Ballivet M, and Bertrand D (1990) 5, 3, and non-3. Three clustered avian genes encoding neuronal nicotinic acetylcholine receptor-related subunits. J Biol Chem 265: 17560-17567.
Craig PJ, Bose S, Zwart R, Beattie RE, Folly EA, Johnson LR, Bell E, Evens NM, Benedetti G, Pearson KH, et al. (2004) Stable expression and characterisation of a human 7 nicotinic subunit chimera: a tool for functional high-throughput screening. Eur J Pharmacol 502: 31-40.[CrossRef][Medline]
Criado M, Mulet J, Bernal JA, Gerber S, Sala S, and Sala F (2005) Mutations of a conserved lysine residue in the N-terminal domain of 7 nicotinic receptors affect gating and binding of nicotinic agonists. Mol Pharmacol 68: 1669-1677.
Czajkowski C, Kaufmann C, and Karlin A (1993) Negatively charged amino acid residues in the nicotinic receptor subunit that contribute to the binding of acetylcholine. Proc Natl Acad Sci USA 90: 6285-6289.
Deneris ES, Connolly J, Boulter J, Wada E, Wada K, Swanson LW, Patrick J, and Heinemann S (1988) Primary structure and expression of 2: a novel subunit of neuronal nicotinic acetylcholine receptors. Neuron 1: 45-54.[CrossRef][Medline]
Duvoisin RM, Deneris ES, Patrick J, and Heinemann S (1989) The functional diversity of the neuronal nicotinic acetylcholine receptors is increased by a novel subunit: 4. Neuron 3: 487-496.[CrossRef][Medline]
Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, and Harpold MM (1996) Comparative structure of human neuronal 2-7 and 2-4 nicotinic acetylcholine receptor subunits and functional expression of the 2, 3, 4, 7, 2, and 4 subunits. J Mol Neurosci 7: 217-228.[Medline]
Figl A, Cohen BN, Quick MW, Davidson N, and Lester HA (1992) Regions of 4.2 subunit chimeras that contribute to the agonist selectivity of neuronal nicotinic receptors. FEBS Lett 308: 245-248.[CrossRef][Medline]
Gerzanich V, Kuryatov A, Anand R, and Lindstrom J (1997) "Orphan" 6 nicotinic AChR subunit can form a functional heteromeric acetylcholine receptor. Mol Pharmacol 51: 320-327.
Harvey SC and Luetje CW (1996) Determinants of competitive antagonist sensitivity on neuronal nicotinic receptor subunits. J Neurosci 16: 3798-3806.
Hussy N, Ballivet M, and Bertrand D (1994) Agonist and antagonist effects of nicotine on chick neuronal nicotinic receptors are defined by and subunits. J Neurophysiol 72: 1317-1326.
Jensen AA, Frolund B, Liljefors T, and Krogsgaard-Larsen P (2005) Neuronal nicotinic acetylcholine receptors: structural revelations, target identification, and therapeutic inspirations. J Med Chem 48: 4705-4745.[CrossRef][Medline]
Lansdell SJ, Gee VJ, Harkness PC, Doward AI, Baker ER, Gibb AJ, and Millar NS (2005) RIC-3 enhances functional expression of multiple nicotinic acetylcholine receptor subtypes in mammalian cells. Mol Pharmacol 65: 1431-1438.
Le Novère N, Corringer P-J, and Changeux J-P (2002) The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 53: 447-456.[CrossRef][Medline]
Lee WY and Sine SM (2005) Principal pathway coupling agonist binding to channel gating in nicotinic receptors. Nature (Lond) 438: 243-247.[CrossRef][Medline]
Lloyd GK and Williams M (2000) Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 292: 461-467.
Luetje CW and Patrick J (1991) Both - and -subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J Neurosci 11: 837-845.[Abstract]
McGehee DS and Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57: 521-546.[CrossRef][Medline]
Millar NS (2003) Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem Soc Trans 31: 869-874.[CrossRef][Medline]
Millar NS (2006) Ligand-gated ion channels, in Encyclopedia of Life Sciences, John Wiley and Sons Ltd, Chichester, UK [doi:10.1038/npg.els.0000154], http://www.els.net/.
Mukhtasimova N, Free C, and Sine SM (2005) Initial coupling of binding to gating mediated by conserved residues in the muscle nicotinic receptor. J Gen Physiol 126: 23-39.
Parker MJ, Beck A, and Luetje CW (1998) Neuronal nicotinic receptor 2 and 4 subunits confer large differences in agonist binding affinity. Mol Pharmacol 54: 1132-1139.
Parker MJ, Harvey SC, and Luetje CW (2001) Determinants of agonist binding affinity on neuronal nicotinic receptor subunits. J Pharmacol Exp Ther 299: 385-391.
Prince RJ and Sine SM (1996) Molecular dissection of subunit interfaces in the acetylcholine receptor: identification of residues that determine agonist selectivity. J Biol Chem 271: 25770-25777.
Sala F, Mulet J, Gerber S, and Criado M (2005) Charged amino acids of the N-terminal domain are involved in coupling binding and gating in 7 nicotinic receptors. J Biol Chem 280: 6642-6647.
Sali A and Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234: 779-815.[CrossRef][Medline]
Schoepfer R, Whiting P, Esch F, Blacher R, Shimasaki S, and Lindstrom J (1988) cDNA clones coding for the structural subunit of a chicken brain nicotinic acetylcholine receptor. Neuron 1: 241-248.[CrossRef][Medline]
Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, and Higgins DG (1997) The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25: 4876-4882.
This article has been cited by other articles:
|
|
 |
|
  N. Innocent, P. D. Livingstone, A. Hone, A. Kimura, T. Young, P. Whiteaker, J. M. McIntosh, and S. Wonnacott {alpha}Conotoxin Arenatus IB[V11L,V16D] Is a Potent and Selective Antagonist at Rat and Human Native {alpha}7 Nicotinic Acetylcholine Receptors J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 529 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. Young, R. Zwart, A. S. Walker, E. Sher, and N. S. Millar Potentiation of {alpha}7 nicotinic acetylcholine receptors via an allosteric transmembrane site PNAS, September 23, 2008; 105(38): 14686 - 14691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zwart, A. L. Carbone, M. Moroni, I. Bermudez, A. J. Mogg, E. A. Folly, L. M. Broad, A. C. Williams, D. Zhang, C. Ding, et al. Sazetidine-A Is a Potent and Selective Agonist at Native and Recombinant {alpha}4{beta}2 Nicotinic Acetylcholine Receptors Mol. Pharmacol., June 1, 2008; 73(6): 1838 - 1843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Gay, R. Giniatullin, A. Skorinkin, and J. L. Yakel Aromatic residues at position 55 of rat {alpha}7 nicotinic acetylcholine receptors are critical for maintaining rapid desensitization J. Physiol., February 15, 2008; 586(4): 1105 - 1115. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Gay, R. J. Bienstock, P. W. Lamb, and J. L. Yakel Structural Determinates for Apolipoprotein E-Derived Peptide Interaction with the {alpha}7 Nicotinic Acetylcholine Receptor Mol. Pharmacol., October 1, 2007; 72(4): 838 - 849. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
), 
), 
), and 
). Additional data were obtained from a stably transfected GH4C1 cell line expressing the human 
) and from a human embryo rhabdomyosarcoma cell line (RD) expressing the native muscle-type nAChRs (
). Results obtained with TMAQ are normalized to the maximum response obtained with 1 mM acetylcholine in the presence of 3 µM atropine for each subunit combination. Data points are means of six to eight independent experiments.
), or r
). B, data obtained with mutated human 
